CPX-351 (VYXEOS)
A Prospective, Single Site, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
What's the purpose of the trial?
The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).
Trial status
Accepting patients
Phase
Phase 2
Enrollment
25
Last Updated
2 months ago
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Allogeneic Stem Cell Transplant is a type of stem cell transplant that utilizes a donor's pre-collected stem cells to rescue the bone marrow from the toxic effects of very high dose chemotherapy.
- CPX-351 is a drug that combines cytarabine and daunorubicin, and is approved for the treatment of acute myeloma leukemia. It is currently being studied for use in several other cancers.
- Cytarabine is an antineoplastic chemotherapy agent that is FDA approved to treat several different kinds of leukemia.
- Hydrocortisone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
- Methotrexate is a chemotherapy medication that may be used in the treatment of many different cancers.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.